血清与腹腔1,3-β-D-葡聚糖联合检测可排除外科重症患者的腹腔内念珠菌感染:一项多中心前瞻性研究
这项法国多中心前瞻性非干预研究纳入199例因腹腔脓毒症接受腹部手术的连续重症患者,主要目的是确定IAC患病率,次要目的是探索血清1,3-β-D-葡聚糖(sBDG)和腹腔1,3-β-D-葡聚糖(pBDG)诊断IAC的价值。结果显示IAC患病率为44%(87/199),主要类型为继发性腹膜炎,63%发生脓毒性休克;多因素分析显示医院获得性起源与更多IAC病例相关(P=0.0399)。pBDG在IAC组中位水平为448 [107.5-1578.0] pg/ml,显著高于非IAC组的133 [16.0-831.0] pg/ml(P=0.0021);pBDG阈值45 pg/ml时阴性预测值为82.3%。联合腹膜透析评分<3、sBDG<3.3 pg/ml(WT)和pBDG<45 pg/ml(WT)的阴性预测值达100%。作者认为该联合策略可有效排除IAC,并可能限制不必要的抗真菌药物暴露。
要点
- 在因腹腔脓毒症接受手术的重症患者中,IAC患病率为44%(87/199),主要类型为继发性腹膜炎,63%发生脓毒性休克。
- 多因素分析显示医院获得性起源与更多IAC病例相关(P=0.0399)。
- pBDG在IAC组中位水平为448 [107.5-1578.0] pg/ml,显著高于非IAC组的133 [16.0-831.0] pg/ml(P=0.0021);pBDG阈值45 pg/ml时阴性预测值为82.3%。
- sBDG(WT法,n=42)第1天在IAC组为5 [3.0-9.0] pg/ml,高于非IAC组的3 [3.0-3.0] pg/ml(P=0.012);sBDG(FA法,n=140)第1天在IAC组为104 [38.0-211.0] pg/ml,高于非IAC组的50 [23.0-141.0] pg/ml(P=0.009)。
- 联合腹膜透析评分<3、sBDG<3.3 pg/ml(WT)和pBDG<45 pg/ml(WT)的阴性预测值为100%。
适用人群与场景
- 因腹腔脓毒症接受腹部手术的连续重症患者(法国多中心前瞻性非干预研究纳入人群)。
诊断标准与关键阈值
- pBDG阈值45 pg/ml用于评估IAC的阴性预测值为82.3%。
- 联合排除标准:腹膜透析评分<3、sBDG<3.3 pg/ml(WT法)和pBDG<45 pg/ml(WT法)三者同时满足时,阴性预测值为100%。
研究设计与关键结果
- 研究类型:法国多中心前瞻性非干预研究;纳入199例因腹腔脓毒症接受腹部手术的连续重症患者;主要终点为IAC患病率,次要终点为sBDG和pBDG诊断IAC的价值。
- 人群特征:男性63%,中位年龄66 [54-72]岁;IAC患病率44%(87/199);主要IAC类型为继发性腹膜炎;脓毒性休克发生率为63%。
- 多因素分析:医院获得性起源与更多IAC病例相关(P=0.0399)。
- pBDG:IAC组中位水平448 [107.5-1578.0] pg/ml,非IAC组133 [16.0-831.0] pg/ml,P=0.0021;pBDG阈值45 pg/ml时阴性预测值为82.3%。
- sBDG(WT法,n=42)第1天:IAC组5 [3.0-9.0] pg/ml,非IAC组3 [3.0-3.0] pg/ml,P=0.012。
- sBDG(FA法,n=140)第1天:IAC组104 [38.0-211.0] pg/ml,非IAC组50 [23.0-141.0] pg/ml,P=0.009。
- 联合腹膜透析评分<3、sBDG<3.3 pg/ml(WT)和pBDG<45 pg/ml(WT)的阴性预测值为100%。
证据类型、等级与局限
- 证据类型:多中心前瞻性非干预研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在需要手术的腹腔感染重症患者中,联合低sBDG、低pBDG和低腹膜透析评分可有效排除IAC,并可能限制不必要的抗真菌药物暴露。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intra-abdominal candidiasis (IAC) is difficult to predict in critically ill patients with intra-abdominal infection, leading to the overuse of antifungal treatments. Serum and peritoneal 1.3-beta-D-glucan (sBDG and pBDG) have been proposed to confirm or invalidate the diagnosis of IAC, but clinical studies have reported inconsistent results, notably because of heterogeneous populations with a low IAC prevalence. This study aimed to identify a high-risk IAC population and evaluate pBDG and sBDG in diagnosing IAC.
METHODS: This prospective multicenter noninterventional French study included consecutive critically ill patients undergoing abdominal surgery for abdominal sepsis. The primary objective was to establish the IAC prevalence. The secondary objective was to explore whether sBDG and pBDG could be used to diagnose IAC. Wako® beta-glucan test (WT, Fujifilm Wako Chemicals Europe, Neuss, Germany) was used for pBDG measurements. WT and Fungitell® beta-D-glucan assay (FA, Associate of Cape Cod, East Falmouth, USA) were used for sBDG measurements.
RESULTS: Between 1 January 2020 and 31 December 2022, 199 patients were included. Patients were predominantly male (63%), with a median age of 66 [54-72] years. The IAC prevalence was 44% (87/199). The main IAC type was secondary peritonitis. Septic shock occurred in 63% of cases. After multivariate analysis, a nosocomial origin was associated with more IAC cases (P = 0.0399). The median pBDG level was significantly elevated in IAC (448 [107.5-1578.0] pg/ml) compared to non-IAC patients (133 [16.0-831.0] pg/ml), P = 0.0021. For a pBDG threshold of 45 pg/ml, the negative predictive value in assessing IAC was 82.3%. The median sBDG level with WT (n = 42) at day 1 was higher in IAC (5 [3.0-9.0] pg/ml) than in non-IAC patients (3 [3.0-3.0] pg/ml), P = 0.012. Similarly, median sBDG level with FA (n = 140) at day 1 was higher in IAC (104 [38.0-211.0] pg/ml) than in non-IAC patients (50 [23.0-141.0] pg/ml), P = 0.009. Combining a peritonitis score < 3, sBDG < 3.3 pg/ml (WT) and pBDG < 45 pg/ml (WT) yielded a negative predictive value of 100%.
CONCLUSION: In critically ill patients with intra-abdominal infection requiring surgery, the IAC prevalence was 44%. Combining low sBDG and pBDG with a low peritonitis score effectively excluded IAC and could limit unnecessary antifungal agent exposure.
TRIAL REGISTRATION: The study was registered with ClinicalTrials.gov (ID number 03997929, first registered on June 24, 2019).
参考来源
- Novy E, Rivière J, Nguyen M, et al. Combination of serum and peritoneal 1.3-beta-D-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study. Crit Care. 2023. PMID: 38037130. doi:10.1186/s13054-023-04761-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。